Early access
Sign in
Taking people in GermanyPhase 1

Tests CTX112 in adults with hard-to-treat lupus, scleroderma or myositis

Tests CTX112 in adults with lupus, scleroderma or myositis that has not responded to treatment.

Key facts

Who runs it
CRISPR Therapeutics AG
Where
Augsburg, Cologne, Frankfurt Am Main, Hanover, and Mainz, GermanySee the 5 sitesAlso in 2 other countries, 8 sites
Trial code
Registry title
A Phase 1 Study of the Safety and Preliminary Efficacy of CTX112 in Adult Subjects With Refractory Autoimmune Disease.
Status
Recruiting
Phase
Phase 1
People taking part
51 people, planned
Started
2 Dec 2025
Expected to end
2 Dec 2030
Type of study
Interventional
Record updated
17 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose autoimmune disease is active and has not responded to treatment: lupus (SLE), systemic sclerosis (SSc) or inflammatory muscle disease (IIM).

Age
18 years or older
Sex
All sexes can join.
Disease stage
Active systemic lupus erythematosus (SLE), systemic sclerosis (SSc) or idiopathic inflammatory myopathy (IIM).

Where in Germany

Also in 2 other countries, 8 sites

  • Universitaetsklinikum AugsburgAugsburg, GermanyTaking people
  • University Hospital Cologne AöRCologne, GermanyTaking people
  • Fraunhofer Institute For Translational Medicine And Pharmacology ITMPFrankfurt Am Main, GermanyTaking people
  • Medizinische Hochschule HannoverHanover, GermanyTaking people
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöRMainz, GermanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests CTX112 in adults with hard-to-treat lupus, scleroderma or myositisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
17 August 2026